Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Pharmacyclics, Inc. Rights Offering Oversubscribed
Pharmacyclics Announces Subscription Price for Rights Offering
Pharmacyclics Sets Record Date for Rights Offering
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Pharmacyclics Files Registration Statement for Rights Offering
Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
Pharmacyclics Receives Nasdaq Notification
Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Pharmacyclics Secures $5.0 Million in Debt Financing
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Pharmacyclics Responds to Nasdaq Letter
Pharmacyclics, Inc. Announces Board and Management Transitions
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Fiscal 2008 Year-End Results
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
RWD Acquisition I LLC Announces Expiration of Tender Offer
Pharmacyclics Announces It Received Nasdaq Notice of Compliance
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission - May 27 2008 12:53AM
RWD Acquisition I LLC Begins Cash Tender Offer for Pharmacyclics, Inc. for $1.05 Per Share - Jun 2 2008 1:28AM
Pharmacyclics Reports Third Quarter 2008 Financial Results
Pharmacyclics Announces It Received Nasdaq Notification
Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
